Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2010 - 2026)

Biocryst Pharmaceuticals has reported Capital Expenditures for 17 years, with the latest figure at $608000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $608000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 36.78% YoY), and the FY2025 full-year result was $608000.0, down 45.91% from the prior year.
• Capital Expenditures for Q1 2026 stood at $608000.0, up from -$1.1 million in the prior quarter.
• The five-year high for Capital Expenditures was $1.1 million in Q2 2025, with the low at -$1.6 million in Q4 2023.
• Historically, Capital Expenditures has averaged $230687.5 across 5 years, with a median of $427500.0 in 2022.
• Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 406.84% — and 2025, when it soared 554.89%.
• Biocryst Pharmaceuticals' Capital Expenditures stood at $526000.0 in 2022, then plunged by 406.84% to -$1.6 million in 2023, then jumped by 141.82% to $675000.0 in 2024, then plunged by 256.74% to -$1.1 million in 2025, then surged by 157.47% to $608000.0 in 2026.
• The last three Capital Expenditures figures came in at $608000.0 (Q1 2026), -$1.1 million (Q4 2025), and $597000.0 (Q3 2025), per Business Quant data.